The present invention relates to a HLA-A*1101- restricted WT1 peptide, and more particularly, to a peptide containing an amino acid sequence composed of nine contiguous amino acids derived from a WT1 protein, which has a binding ability to HLA-A*1101 molecule and has a CTL-inducing ability； and to a peptide dimer formed by combining two peptide monomers containing an amino acid sequence composed of nine contiguous amino acids derived from a WT1 protein with at least one cysteine residue via a disulfide bond, which has a binding ability to HLA-A*1101 molecule and has a CTL-inducing ability. The present invention further relates to a polynucleotide encoding the peptide and a pharmaceutical composition comprising the same for the treatment and/or prophylaxis of cancers.本發明係有關HLA-A*1101限制性WT1胜肽，詳細而言，係有關一種含有由源自WT1蛋白質之9個連續胺基酸所構成之胺基酸序列的胜肽，該胜肽具有與HLA-A*1101分子結合能力、且具有CTL誘導能力；以及有關一種以含有至少具有1個半胱胺酸殘基之源自WT1蛋白質之9個連續胺基酸所構成之胺基酸序列的2個胜肽單體經由二硫鍵而互相結合的胜肽二聚物，該胜肽二聚物具有與HLA-A*1101分子結合能力、且具有CTL誘導能力；本發明又有關編碼該胜肽之聚核苷酸、包含該等之癌症治療及/或預防用醫藥組成物等。
